Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
A new scientific publication from AroCell confirming the value of AroCell TK 210 ELISA as a tool in drug discovery and development | ||
By: Nasdaq / GlobeNewswire - 11 Dec 2018 | Back to overview list |
|
A peer-reviewed article has been published in the journal Nucleosides, Nucleotides and Nucleic Acids, entitled “Doxorubicin effects on leukemia and breast cancer cells in culture on the Thymidine Kinase 1 protein levels using AroCell TK 210 ELISA: a tool for drug development”, written by Kiran Jagarlamudi et al. The results have previously been presented at a scientific meeting in Gdansk last year.
“We are delighted with the results of this scientific study, which demonstrate that the AroCell TK 210 ELISA can be used to measure TK 1 protein as a biomarker for in vitro drug effects, particularly, for drugs targeting cell proliferation and DNA damage.” says Michael Brobjer, AroCell’s new CEO. “These results support AroCell’s focus on the application of the TK 210 ELISA in drug discovery and development. They demonstrate the potential of TK1 as a translational biomarker that can be used to evaluate potential drug candidates before they are moved into xenograft and other preclinical investigations.” AroCell TK 210 ELISA is an easy-to-use, robust and reproducible assay. In addition, it can be run on standard ELISA equipment commonly used in many laboratories. The publication is available on: https://www.tandfonline.com/doi/full/10.1080/15257770.2018.1478094 For more information: This information was submitted for publication through the agency of Michael Brobjer, December 11, 2018 at 08:30 hours. About AroCell
Attachment |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |